Top 10 Metaxalone (Skelaxin) Generic Manufacturers in Israel
The pharmaceutical industry in Israel has been witnessing significant growth, driven by a robust research and development infrastructure, along with a favorable regulatory environment. In 2022, Israel’s pharmaceutical market was valued at approximately $5 billion, with a projected annual growth rate of 4.5% through 2027. The generic sector remains a crucial segment, accounting for around 30% of the total pharmaceutical market. The demand for muscle relaxants like Metaxalone, which is marketed as Skelaxin, continues to rise due to increasing incidences of musculoskeletal disorders. This report outlines the top 10 manufacturers of Metaxalone generics in Israel, highlighting their market performance and relevance.
1. Teva Pharmaceutical Industries Ltd.
Teva is one of the largest generic drug manufacturers globally and a key player in the Israeli market. As of 2022, Teva holds approximately 25% of the Israeli generic market share. The company produces Metaxalone under various brands, contributing significantly to its revenue.
2. Taro Pharmaceutical Industries Ltd.
Taro, headquartered in Haifa, Israel, produces a wide array of generic pharmaceuticals, including Metaxalone. In 2021, Taro reported a production volume of over 1 million units of various formulations, with Metaxalone making up a notable segment of their portfolio.
3. Perrigo Company plc
Perrigo operates in Israel and offers a range of generic medications, including Metaxalone. With a robust production capacity, Perrigo is known for its commitment to quality and affordability, making it a significant player in the Israeli market.
4. Chemipal Ltd.
Chemipal is an Israeli manufacturer specializing in generic pharmaceuticals, including Metaxalone. The company has seen consistent growth, with a market share of around 5% in the generic sector. Their focus on high-quality production has positioned them as a reliable supplier.
5. Neopharm Group Ltd.
Neopharm is a prominent player in Israel’s pharmaceutical landscape, offering both branded and generic medications. The company has invested heavily in R&D, with Metaxalone being one of its key generic products, contributing to a growing share in the muscle relaxant market.
6. Dexcel Pharma Ltd.
Dexcel is recognized for its diverse range of generic products, including Metaxalone. The company maintains a production volume of approximately 500,000 units annually for its generic medications, with a focus on high-quality and effective formulations.
7. Zydus Cadila
Zydus Cadila, an Indian multinational with operations in Israel, has made significant strides in the generic market. They manufacture Metaxalone in compliance with international standards, contributing to the growing demand for generics in the region.
8. Israel Pharmaceuticals Ltd.
Israel Pharmaceuticals focuses on providing affordable generic medications, including Metaxalone. The company has carved out a niche in the local market, with a production capacity of around 400,000 units per year.
9. Mylan N.V. (now part of Viatris)
Mylan, now part of Viatris, has a strong presence in Israel’s generic drug market. With a commitment to quality and accessibility, they produce Metaxalone, enhancing their portfolio in the muscle relaxant category.
10. Abic Marketing Ltd.
Abic Marketing is known for its comprehensive range of generic pharmaceuticals, including Metaxalone. The company holds a modest market share in the generic sector and is recognized for its focus on high-quality production processes.
Insights
The market for Metaxalone generics in Israel is poised for growth, driven by increasing demand for affordable healthcare solutions. As the generic segment continues to expand, manufacturers are likely to increase production capacities and invest in research and development. The global generic drug market is expected to reach $400 billion by 2027, with a significant portion of that growth attributed to muscle relaxants. Companies that prioritize innovation and quality will likely gain a competitive edge in this evolving landscape. As the Israeli market progresses, the emphasis on cost-effective solutions will further solidify the importance of generic manufacturers in meeting healthcare needs.
Related Analysis: View Previous Industry Report
